Asia Partnership Conference of Pharmaceutical Associations (APAC) Report on Regulatory Agility Implemented During the COVID-19 Pandemic: Inspiring Partnerships and Recommendations for the Way Forward

Sannie Siaw Foong Chong1,2 · Masaaki Kanno3 · Alice Seat Mee Chee4 · Siew Mei Long5 · Stephanie Hui Min Ong6 · Usanee Harnpramukkul7 · Richard Simon R. Binos8

Received: 7 March 2022 / Accepted: 15 July 2022 / Published online: 29 September 2022 © The Author(s) 2022

Abstract
Purpose  Asia Partnership Conference of Pharmaceutical Associations (APAC) promote regulatory agility of four important best practices i.e. reliance, digital platform, accepting electronic document and process integration. Dialogues and strong partnership witnessed reforms and efficiencies amidst the pandemic. In tracking the progress of regulatory agility, APAC identifies areas for improvement and recommends prioritizing these areas for change.

Methods  As one voice, 13 main industry associations under the umbrella of APAC sent joint letters to our National Regulatory Authorities (NRAs) with a call to maintain regulatory agility and consider new ways of working. Consequently, APAC surveyed its member associations to measure regulatory agilities implemented by the NRAs during 2020 and 2021 in view of the pandemic.

Results  This paper reports progress in implementing regulatory agility, e.g. the number of economies that can accept electronic Certificate of Pharmaceutical Products (eCPP) has reached 100% for the economies that require CPP and more than 90% can waive onsite inspection in the presence of Good Manufacturing Practice (GMP) certificate and/or inspection report. The paper also features the progress made in Malaysia, the Philippines, and the ASEAN (Association of South East Asian Nations) regional reliance initiative to reduce inefficiencies and duplications.

Conclusions  We have demonstrated the power of working together to enable regulatory agilities and efficiencies. APAC will continue to track the progress of all economies including India within the areas for improvement prioritized and discussed in this paper. APAC is also committed to working with key stakeholders including our NRAs in Asia to sustain and enable a new era of innovation ushered in by COVID-19 to benefit patients.

Keywords  Partnership · Regulatory agility · COVID-19 · APAC · NRAs

Abbreviations
2D  Two-dimensional
AJA  ASEAN Joint Assessment

© The Author(s) 2022

Sannie Siaw Foong Chong
sannie.chong@merck.com

1 Pharma Technical Regulatory Policy and International Operations, Roche Singapore Technical Operations, F. Hoffmann La-Roche Ltd., Singapore, Singapore
2 Present Address: Global Regulatory Policy, Global Regulatory Affairs and Clinical Safety, Merck Research Laboratories, MSD, Singapore, Singapore
3 Overseas Regulatory Office, Regulatory Affairs Department, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan
4 Pharmaceutical Association of Malaysia, Petaling Jaya, Malaysia
5 Merck Sharp & Dohme, Petaling Jaya, Malaysia
6 Sanofi, Petaling Jaya, Malaysia
7 Global Regulatory Affairs – International, Pfizer, Bangkok, Thailand
8 Pharmaceutical and Healthcare Association of the Philippines, Makati, Philippines

© Springer
In the second half of 2020, APAC recognized the challenges posed by the ongoing COVID-19 pandemic to our NRAs. To ensure the continuity of supply of medicines and treatment to patients, APAC’s 13 main industry associations sent a joint letter to the NRAs in Asia in July 2020 to work in partnership and consider new ways of working.

This is the first time, all the member associations, except the Organization of Pharmaceutical Producers of India (OPPI) under the umbrella of APAC have collectively communicated our objectives as one voice in a form of a joint letter to commend the efforts of NRAs in practicing regulatory agility. Accordingly, APAC recommends four important best practices:

1. Collaborative, coordinated scientific assessment leveraging on reliance practices;
2. Enhanced use of digital platform for communication;
3. Acceptance of electronic document; and
4. Integrate and streamline regulatory processes.2

To ensure efficiency and avoid duplicative review, APAC recommends good reliance practices by leveraging stringent work already conducted by leading NRAs as shown in Diagram 1. The use of digital platforms (e-labeling, traceability of serialization) improves the accessibility of approved medical information and helps in securing pharmaceutical supply chains against counterfeiting. On the other hand, shifting the requirement from wet signatures and legalization to electronic-based certification ensures the continuity of the regulatory processes by eliminating physical steps in the process. Lastly, integrating and streamlining the regulatory processes including multiple production sites in one license facilitates supply flexibility while eliminating duplicative activities.

Following the letter, APAC member associations worked with the respective NRAs towards implementing the recommendations. On 13 April 2021, we the industry associations met with the NRAs in the annual APAC meeting.3 We decided to present a joint Thank You letter to all our regulators in Asia after the APAC meeting. In June to July 2021, APAC sent a follow-through letter 4 to thank the regulators for taking action and practicing regulatory agility during global crisis; as well as to highlight regulatory processes that remain challenging for patients’ access. To determine

---

1 APAC is an industry-driven initiative led by research and development (R&D)-based pharmaceutical associations, aiming to fulfill its mission of expediting the launch of innovative medicines for the people in Asia.

2 https://apac-asia.com/images/achievements/pdf/10th/APAC%20letter%20related%20to%20COVID-19.pdf

3 10th APAC Virtual Conference Theme: Overcoming COVID-19 and Taking on New Innovative Challenges for the Next Decade in Asia.(2021); https://apac-asia.com/achievements/10th.apac.html.

4 APAC Thanks Letter Related to Covid-19 (2021). https://apac-asia.com/images/achievements/pdf/10th/APAC Thanks Letter related to COVID-19.pdf.
the progress and response of the NRAs to the recommendations mentioned in the letters, APAC decided to measure the status of regulatory landscape of our NRAs.

**Methodology**

In July 2020 and December 2021, the APAC conducted a survey to measure the implementation of regulatory agilities recommended by APAC in all 11 economies in Asia.

**Survey Participants**

Apart from OPPI, the survey was sent to all the 13 APAC member associations. Since there are two member associations in China and South Korea, the responses from the same economies were considered as one valid response to avoid duplication.

**Materials**

A progress status form was prepared. It contained question—response type of questionnaires that consisted of four sections with questions designed to determine the level of regulatory agility practiced by the NRA. The progress status form can be found at the link.\(^5\)

**Diagram 1** Examples of Challenges and APAC’s recommendations in implementing regulatory agilities.

**Procedure**

**Preparing the Letters**

Prior to the distribution of the APAC letter to the respective NRAs, signature of each member association was required. All members reviewed and signed the letter except OPPI. Consequently, APAC did not send the letters to the NRA of India. The APAC secretariat sent the letters to the NRAs through the names and emails provided by the member associations. The member associations were included in the same email in case of clarifications or follow-up actions.

The recipients of the APAC letters were:

| Economies | Abbreviations | National Regulatory Authority (NRA) |
|-----------|---------------|-----------------------------------|
| Vietnam   | VN            | Drug Administration of Vietnam (DAV) |
| Hong Kong | HK            | Drug Office, Department of Health (DOH) |
| Singapore | SG            | Health Sciences Authority (HSA) |
| Indonesia | ID            | National Agency of Drug and Food Control (BPOM) |
| China     | CN            | National Medical Products Administration (NMPA) |

\(^5\) Progress-Status Feedback by each association_Final (002).xlsx (live.com)

 Springer
Economies | Abbreviations | National Regulatory Authority (NRA)
--- | --- | ---
Malaysia | MY | National Pharmaceutical Regulatory Agency (NPRA)
South Korea | SK | Ministry of Food and Drug Safety (MFDS)
Japan | JP | Pharmaceuticals and Medical Devices Agency (PMDA)
Philippines | PH | Philippines Food and Drug Administration (PFDA)
Taiwan | TW | Taiwan Food and Drug Administration (TFDA)
Thailand | TH | Thailand Food and Drug Administration (Thai FDA)

### Collecting the Data

Data collection commenced in the second half of 2020, with reference to the direct response of the government officials to the letters or from the industry associations.\(^6\) Official replies from Taiwan FDA\(^7\) and HK MOH were received in later part of 2020. To obtain feedback, APAC member associations also conducted dialogue sessions to follow-up with our NRAs.

To track progress, APAC conducted a survey to all APAC members on 24 August 2021 and received responses from member associations in China, Hong Kong, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam.

When needed, APAC also referred to peer-reviewed publications [1], official websites, APAC analysis reports\(^8\) or contacted member associations directly for collecting retrospective baseline data (prior to COVID-19 pandemic).

### Results

#### Market Authorization Agilities/Reliance Including Inspection, Import Re-Testing and Post-Approval Agilities

CPP is part of the registration pathways including reliance pathways in Indonesia, Malaysia, Philippines, South Korea, Taiwan, Thailand, and Vietnam as shown in Fig. 1a. Different from its original intent, CPP is required while these NRAs continue to conduct full evaluation. On the other hand, Hong Kong used CPP to replace full or partial review as defined by the World Health Organization (WHO) [2]. It is worth noting that China, Japan, and Singapore do not require CPP though companies may choose to use CPP in Singapore as proof of approval. Recently, South Korea too removed CPP from its registration requirement [3]. As of Q4 2021, Hong Kong has one standard pathway that relies on CPP, while reliance pathways exist in Indonesia, Malaysia, Singapore, Taiwan, Thailand, and Vietnam based on assessment report or CPP of the reference agencies for evaluation of all products. Although reliance pathway is not available for general product registration in China, Japan, Philippines, and South Korea, these economies may leverage reliance practice to approve COVID products as shown in Fig. 1b.

Import re-testing is applicable in all the economies for vaccines and some biologics (e.g. blood products) as shown in Fig. 1c; of which Hong Kong, Indonesia, Malaysia, and Singapore may conduct desktop review and/or leverage reliance of reference agencies’ approval to fulfill re-testing assessment. The Philippines revised import re-testing requirement in 2021 from applicable to all biologics to applicable to vaccines and some biologics only. This is similar to that practiced by most of the ASEAN countries [4]. Similarly, the requirement in Vietnam also applies to vaccines and some biologics by Q4 2021 [5]. Japan can waive off import re-testing based on Mutual Recognition Arrangement (MRA) while this arrangement is currently absent in China and South Korea.

As of Q4 2021, Hong Kong, Indonesia, and Singapore apply reliance to post-approval variations and indications while this is under discussion in Malaysia and Philippines as shown in Fig. 1d.

#### Digital Platform (e-Labeling, Traceability or Serialization)

As of Q4 2021, Japan implemented e-labeling [6], while Indonesia, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand fully adopt it for COVID-19 products. China, Hong Kong, and Vietnam have yet to implement...
**Use of CPPs as of Q4 2021.**

- CPP is either removed/not required or to replace all reviews fully or partially.
- CPP is used to replace some reviews fully or partially.
- CPP is part of standard registration/reliance but does not replace reviews fully or partially.

**Use Reliance Pathways (assessment report or CPP) for Regular Medicines vs COVID Medicines as of Q4 2021.**

**Expansion of reliance to waive off redundant re-testing upon importation as of Q4 2021.**

**Implementation of reliance to cover new indications and post-approval variations as of Q4 2021.**

---

**Fig. 1** Implementation of reliance as of Q4 2021
Therapeutic Innovation & Regulatory Science (2023) 57:12–25

17

Fig. 2 Implementation of digital platform as of Q4 2021

a Implementation of eLabeling as of Q4 2021.

b Implementation of serialization as of Q4 2021.

e-labeling as shown in Fig. 2a. Figure 2b shows full implementation of serialization in South Korea as of Q4 2021. China, Indonesia, Japan, Taiwan, Thailand, and Vietnam initiated traceability through barcodes or QR codes, whereas the implementation in Hong Kong, Malaysia, Philippines, and Singapore is on a voluntary compliance.

From Paper to Electronic-Based Document

In Q1 2021, CPP is not required in Japan and Singapore; and both economies accepted electronic GMP (eGMP) certificate when applicable. Indonesia and Malaysia accepted eCPP and eGMP certificate. China and Thailand accepted eCPP as is but require additional legalization for eGMP certificate. By Q4 2021, all economies accepted eCPP as is. However, China, Philippines, Thailand, and Vietnam require additional legalization on eGMP certificate as shown in Fig. 3.

For post-approval variations, Hong Kong may still require additional legalization for eGMP certificate, https://www.drugoffice.gov.hk/eps/do/en/doc/guidelines_forms/copGuide.pdf?v=lvxgyq. [35]
Integrating and Streamlining Processes (e.g. Multiple Sites in One License/Non-site-specific Stability Data)

In Q1 2020, China, Indonesia, Japan, Malaysia, Singapore, South Korea, and Taiwan practiced multiple sites in a single license. Among them, some economies apply multiple sites in a single license for specific procedures and product categories only and not for all the evaluation pathways. By Q4 2021, both Philippines and Thailand also accepted multiple sites in a single license for COVID products as shown in Fig. 4a. Hong Kong only allows a single drug substance (DS) and a single drug product (DP) manufacturer in one license [7].

Site-specific stability data remains largely a challenge in Asia as shown in Fig. 4b. On the contrary, this is not a requirement in Hong Kong, Japan, and Singapore. As of Q4 2021, Japan aligns with Q12 [8] of the ICH as shown in Fig. 4c. The alignment to ICH Q12 is currently under review in China, Singapore, and South Korea.

All the NRAs implemented efficient measures as of Q4 2021 to substitute on-site inspection as shown in Fig. 4d. China has adopted remote inspection [9, 10], but efficiency as measured by utilization of PIC/S GMP inspection reports or with a MRA is still under exploration.

Discussion

Progress in Implementing Regulatory Agility, and Areas to Prioritize Improvements Include:

Market Authorization Agilities/Reliance

There continues to be a long review and approval process in economies that require CPP. APAC recommends removing the CPP when it does not replace full or partial assessment based on its original intent defined by the WHO [2, 11, 12]. This will eliminate resource wastage in redundant document review activities. The NRAs have made great strides toward approving COVID-19 products by leveraging assessments performed by the reference agencies in reaching their own decisions within a shorter timeline than the standard procedures. APAC recommends integrating approval process based on reliance into the system to approve all product types and all submission applications, including line extensions and post-approval variations. Removing or reducing import re-testing based on reliance is a welcome development. APAC recommends retaining this agility and operationalizing beyond COVID-19 products. Aligned with the COVID-19 registration experience, the Emergency Use Authorization (EUA) pathway demonstrates how the expedited pathway can work in reality, whereby reliance on stringent regulatory authorities helped facilitate the process [13]. NRAs can leverage the processes and procedures gained from EUA to develop future expedited pathways moving forward.

Digital Platform (e-Labeling, Traceability or Serialization)

Japan has implemented e-labeling with the availability of electronic product information (ePI). Serialization is fully implemented in South Korea, although ePI is yet to be made available for all products. Nevertheless, for COVID-19 products all NRAs except China, Hong Kong and Vietnam have implemented ePI. Traceability is initiated in all economies with some on a voluntary compliance. Traceability and ePI ensure faster deployment of product information and improves health system resilience. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) supports the use of globally harmonized and standardized two-dimensional (2D) barcodes to provide a direct link from packaging to electronic product information (e.g., 2D barcodes based on International Organization for Standardization / International Electrotechnical Commission (ISO/IEC) 16022 Data Matrix barcode standard) [14].

From Paper to Electronic-Based Document

Economies that require CPP can accept eCPP as is. In the case of eGMP certificate, additional steps in legalization including embassy stamps and wet signatures are required. APAC recommends removing these legalization processes since checking and verifying electronically is feasible.

Integrating and Streamlining Processes (e.g. Multiple Sites in One License/Non-site-specific Stability Data)

ICH and WHO guidelines classify adding a manufacturing site as a post-approval variation, resulting in multiple sites in one product license [15, 16]. In contrast, site addition approved as a new drug application will result in one site in one license and consequently the need for site-specific stability data. This approach complicates and hinders the addition of multiple sites, without enhancing the value of regulatory oversight [1]. The recommendation is to adopt the practice of multiple sites in a single license, in line with ICH and WHO guidance. Waiver of site-specific stability studies on multiple drug substance and product sites need to be considered or batches reduced to ensure timely and stable supplies, and these best practices are essential to ameliorate the impact of public crisis on the availability of medicines including vaccines. Singapore removed site-specific stability data in 2020 [17], a reference that NRAs could potentially leverage to make the same change in reducing site-specific stability data.
ICH and PIC/S are platforms for disseminating regulatory information and for building knowledge and trust among NRAs. Japan is exemplary in embracing international guidelines including ICH Q12 [1]. Likewise, all NRAs should rigorously implement harmonized ICH principles of Q12 as regulatory standards to facilitate the review and

- **a** Multiple DS and DP sites in a single license as of Q4 2021.
- **b** Requirement for site-specific stability data as of Q4 2021.
- **c** Alignment with ICH Q12 as of Q4 2021.
- **d** Efficient measures to substitute on-site inspection as of Q4 2021.

Fig. 4 Streamlining and integrating processes as of Q4 2021
provide a single technical basis for approval. As shown in Fig. 5, there exist efficient measures to substitute on-site GMP inspection, including the adoption of remote inspection. It is envisaged that these measures under COVID can become a long-term approach and can be formulated into the process of business-as-usual moving forward [18].

The Importance of Inspiring Partnership

Case Study: The Philippines FDA’s Reforms Amidst the Pandemic

The Philippines FDA (PFDA) was under new management just months prior to the pandemic. This reopened communication lines between regulators and industry stakeholders. To improve regulatory services, the PFDA presents reform plans and gathers industry concerns and suggestions through the reinstigation of the quarterly dialogue. Consultative and/or pre-submission meetings with individual companies were allowed on a case-to-case basis, and opportunities for discourse on regulatory findings (e.g. deficiencies, disapprovals) were considered. PFDA, in consultation with the industry, started revisiting existing standards and policies, welcomed inputs from regional and global associations such as APAC and participated in conferences and fora. The collaborative mindset helped PFDA and the Philippines as a whole to better manage the then-approaching crisis.

While the Philippines was described as having the “longest” and “strictest” lockdown in the world, the partnership continued and grew stronger. In the last two years, the PFDA has worked on regulatory policies that address concerns raised by the industry. The PFDA drafted policies and consulted with the industry, while the industry prepared suggestions and recommendations for its improvement by highlighting international best practices and standards. Among other, these reforms include: (1) the shift of focus to risk management plans and global post-marketing surveillance activities [19]; (2) limiting lot release certification requirements to vaccines, toxoids, and immunoglobulins [4]; (3) acceptance of electronic signatures, and eCPP; (4) digitalization of certain regulatory processes [20–22]; and (5) introduction of facilitated registration procedures through reliance [23, 24].

Regulatory reliance was among the reforms that were fast-tracked by the pandemic experience. In order to make available the latest COVID-19-related technologies (e.g. diagnostics, vaccines, and therapies) at the earliest time possible, the PFDA needed an alternative registration scheme that relied on the reviews already conducted by stringent regulatory authorities. The EUA pathway was instituted which relied on assessment reports issued by identified regulatory authorities. The EUA scheme served as a learning experience for both regulators and participating industry stakeholders, and it made both parties realize that the Philippine industry is capable to be at par with regulations of neighboring Asian countries [25]. As a result, Philippines explored other agilities, including: (1) multiple sites under a single license; (2) non-site-specific stability reports; and (3) “smart” or electronic labeling.

Although some of the agilities initiated are yet to be formalized into policy, the experience of regular exchange between parties helped in ensuring that regulatory interventions were quick and targeted, especially as companies strive to bring COVID-19 related technologies to Filipino patients. APAC anticipates that the experience of working in this new
framework will accelerate further reforms—a feat that was not possible before.

**Box 2: The Philippines case study**

**The Philippines Case Study: Gaps and recommendations**

- Implementation of Regulatory Reliance. Reliance registration schemes have recently been finalized[36] for non-COVID drugs. While inputs have been provided and incorporated, we are yet to see the actual implementation and its impact.
- Availability of e-labeling. There is no formal policy yet allowing the use of e-labels. A pilot study needs to be conducted and revisions in the existing policy – that requires paper labeling information – be instituted.
- Multiple sites in one license. The FDA requires “one-site-one-license” for all drug products, making it difficult to arrange alternative sources for the same product, especially during shortages. Policy revision is necessary, taking note of the best practices from other NRAs.

### The Outcome of Partnership in Advancing Regulatory Transformation in Asia

#### Case Study: Malaysia NPRA at the Forefront of Digitalization and Modernization

There is an increasing need for regulators to innovate and collaborate to inspire impact, facilitate, and sustain earlier access of medicinal products to patients. The National Pharmaceutical Regulatory Agency of Malaysia (NPRA) has been exemplary in leading system modernization particularly in the areas of reliance, digitalization, and access to innovation.

Following the success of the seven participating NRAs jointly reviewing the anti-malaria drug in 2017 facilitated by WHO, Malaysia published the ASEAN Joint Assessment (AJA) Procedure Guideline and ASEAN Priority Disease List in 2020 [26]. NPRA received a proposition from the Pharmaceutical Association of Malaysia (PhAMA) to improve and optimize the AJA and the proposal was brought up to the ASEAN Joint Assessment Coordinating Group (JACG) for consideration [27]. These recommendations derived from leveraging best practices observed from successful international collaborations such as ACCESS Consortium [28] and Project ORBIS [29], which includes but not limited to (a) expanding the eligibility list to all diseases and product types; and (b) streamlining the administrative procedures to improve the efficiency and pace of the work sharing initiatives among the ASEAN countries. The optimization of AJA will encourage greater industry participation and unleash the true potential of AJA benefiting both regulators and industry alike—leading to earlier regulatory access of innovative medicines to patients. At the 6th JACG meeting on 28–29 October 2021, it has since been agreed to enhance the AJA procedure with the aim to overcome the challenges observed, to clarify steps in the AJA process and timeline, to update the Frequently Asked Questions (FAQ) document and to expand the list of priority products. The AJA Guideline and ASEAN Priority Disease List have been updated to incorporate many of the recommendations.

Akin to global regulators placing prominent emphasis on regulatory reliance, the NPRA is looking at piloting a project to utilize the assessment reports from other reference agencies in addition to the European Medicines Agency (EMA) and the US FDA in consideration of expanding the scope of the facilitated review pathway to maximize the potential of reliance. Additionally, Malaysia is also exploring and considering concepts of reliance for post approval product quality lifecycle by collecting data to see feasibility of including this process in future Malaysian Variation Guideline [30] revisions. Malaysia with the assistance from PhAMA is also open to further understand the Post Approval Change Management Protocol (PACMP) and ICH Q12 [15] on the implications of the variation reviews and approvals.

In the aspect of digitalization, the Ministry of Health (MOH) Malaysia is fully supportive of the initiatives and is looking to expedite the adoption of e-labeling in Malaysia and the possible alignment to the planned implementation of serialization in 2023. A joint Industry-MOH working group led by MOH has been formed to work further on the proposal. The collaborative efforts by the team will include a roadmap review, stakeholder mapping, survey on acceptability of e-labeling in Malaysia, and other necessary actions.

NPRA is moving towards modernization of regulatory submission systems to ensure the highest level of work efficiencies to drive better outcomes for patients. Accordingly, Malaysia has made a commitment to prioritize the optimization of the online system QUEST as an important measure to address industry’s concerns. In particular, with the planned system upgrade, NPRA has committed to explore the possibility to allow the submission of multiple sites on a single license for products and parallel/multiple submissions of additional indication applications. In scope to pave ways for innovative pathways or strategies in Malaysia, Real World Data/Evidence (RWD/E) capacity building with the introduction of the concept to facilitate decision-making, as well as increasing awareness and understanding of the implementation of RWD/E in regulatory decision-making are in progress. RWD/E has the potential to accelerate the delivery of safe and cost-effective therapeutic interventions and to support the expansion of approved therapeutics through a new indication, formulation, and label expansion [31].
Box 3: Malaysia case study

Malaysia case study: Gaps and recommendations

ASEAN Joint Assessment:
- **Gap**: Need for process optimization and increased transparency (including on timelines).
- **Recommendation**: Political commitment, appropriate governance structures and funding, and well-functioning project management with adoption of global best practices are key to support its implementation.

Fostering Reliance:
- **Gap**: Need to further maximize the potential of reliance.
- **Recommendation**: To expand the scope of facilitated review pathway including for post approval product quality lifecycle management.

Digitalization (E-labeling):
- **Gap**: Cost to acquire and build supplementary technological system to support e-labeling and communication to facilitate the implementation of e-labeling and future enhancement.
- **Recommendation**: Planning and harmonizing labeling information to comply with local regulations along with effective collaboration between the industry and regulators to design a robust proposal for Malaysia.

Modernization of Regulatory Submission:
- **Gap**: Lack of expertise and inadequate experience in the selected field needs to be improved for better work efficiencies and modernized approaches to drive better health outcomes for patients.
- **Recommendations**: Optimization of the online QUEST system to support all types of regulatory submissions; and capacity building on the use of Real-World Data/Evidence (RWD/E) to facilitate regulatory decision-making, and the development of an RWE regulatory framework.

Conclusion

Improving in Key Areas

APAC will continue to track the progress of all economies including India within the areas for improvement prioritized and discussed in this paper.

Supporting a Regional Reliance Program

ASEAN will be implementing ASEAN Pharmaceutical Regulatory Policy (APRP) [32] to align with principles of international standards and best practices, eliminate country-specific requirements and promote the concepts of reliance and MRAs. Upon adoption of the ASEAN Pharmaceutical Regulatory Framework Agreement which is legally binding [33], the subsequent step is to develop the ASEAN Pharmaceutical Regulatory Framework (APRF). APAC aims to contribute as interested parties on the scientific, regulatory and technical arm of APRF. Collectively, APAC may also consider ways to support a regional reliance program coordinated for multiple regulators to reach their regulatory decision around the same time [2].

Advancing Digital Transformation

With an increasingly fast digitalization and shifting to sustainable operation models, strong partnership between NRAs and APAC can expedite the adoption of telehealth and digital technologies ushered in by COVID-19 [34]. APAC is committed to working with key stakeholders including our NRAs to sustain and enable a new era of innovation to benefit patients without compromising the robust standard of approval.

Acknowledgements

The authors acknowledge Madam Rosilawati Binti Ahmad, Madam Siti Hidayah Binti Kasbon and team from Malaysia NPRA, and Dr Oscar G. Gutierrez Jr from the Philippines FDA for reviewing the case study of their organizations. The authors also thank Mika Niboshi for assisting in the APAC letters, all the 13 APAC member associations for responding to the survey and funding the publication of the paper.

Author Contributions

SSFC led the drafting of the paper. SSFC and KM developed the APAC letters and surveys. KM sent the letter and the circulation of the survey. RB drafted the case study of the Philippines; while ASMC, SHMO and SML drafted the case study of Malaysia. UH discussed the APRP and APRF. RB, KM and SSFC led the analysis of the survey and creation of the figures. Each author reviewed and approved the final version of the paper.

Declarations

Competing interest

The authors declare no potential conflicts of interest with respect to the research, and/or publication of this paper. The contents of this manuscript do not represent the positions of any of the authors’ respective organizations.

Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. 
## Appendix A

APAC member associations:

| Association | Description |
|-------------|-------------|
| HKAPI       | The Hong Kong Association of the Pharmaceutical Industry |
| IPMG        | International Pharmaceutical Manufacturers Group |
| IRPMA       | International Research-based Pharmaceutical Manufacturers Association |
| JPMA        | Japan Pharmaceutical Manufacturers Association |
| KPBMMA      | Korea Pharmaceutical and Bio-Pharma Manufacturers Association |
| KRPIA       | Korean Research-based Pharmaceutical Industry Association |
| OPPI        | Organization of Pharmaceutical Producers of India |
| PhAMA       | Pharmaceutical Association of Malaysia |
| Pharma Group| PG Pharma Group Vietnam |
| PHAP        | Pharmaceutical and Healthcare Association of the Philippines |
| PhIRDA      | China Pharmaceutical Innovation & Research Development Association |
| PReMA       | Pharmaceutical Research & Manufacturers Association |
| RDPAC       | R&D-based Pharmaceutical Association Committee |
| SAPI        | Singapore Association of Pharmaceutical Industries |

In addition, PG Pharma Group Vietnam participates in the activities of APAC Regulations and Approvals Expert Working Group (RA-EWG) as an observer.

See Fig. 6.
References

1. SF Chong, M Kim, M Limoli, E Obscherning, P Wu, L Feisee, N Nakashima, JCW Lim (2021). Measuring Progress of Regulatory Convergence and Cooperation Among Asia-Pacific Economic Cooperation (APEC) Member Economies in the Context of the Covid-19 Pandemic. Ther Innov Regul Sci 55, 786–798 (2021); https://doi.org/10.1007/s43441-021-00285-w.

2. WHO Good Reliability Practices, WHO Expert Committee on Specifications for Pharmaceutical Preparations, WHO Technical Report Series 1033, 55th Report, Annex 10, 237–257 (2021). https://apps.who.int/iris/bitstream/handle/10665/340323/9789240020900-eng.pdf.

3. Korea Ministry of Food and Drug Safety, Regulations on the Authorization Declaration and Examination of Items of Medicines, 043–719–2607 (2021). https://www.law.go.kr/%ED%89%EC%9A%99/%EA%B7%9C/%EC%9B%99/%EC%9D%98/%EC%95%BD/%ED%98%88/%EC%9E%AC/%EB%AA%A8/%ED%97%88/%ED%95%9C/%ED%95%9C/%EB%8B%8A/%EC%9C%84/%EC%95%9C/%EB%8B%8A/

4. IFPMA, Improving Patient Safety and Health Systems Resilience Through the Use of Electronic Labeling, 1–6 (2021). https://www.ifpma.org/resource-centre/position-paper-use-of-electronic-labeling/.

5. Hong Kong DoH, Supplementary Notes for Application for Registration of Biological Products Involving Alternative/Back Up Manufacturer(s) for Manufacturing Steps (2021). https://www.drugoffice.gov.hk/eps/do/en/doc/guidelines_forms/Supplementary_Notes_for_Application_of_Registration_of_Biopharmaceuticals.pdf?view=79mwi.

6. Japan PMDA ICH-Q12 Pharmaceutical Life Cycle Management (2021). https://www.pmda.go.jp/int-activities/int-harmony/ich/0041.html.

7. CFDI carried out Remote Inspection of Imported Drugs for Pilot study in Nov. 2020. https://www.cfdi.org.cn/resource/news/12921.html.

8. Notifications for Remote Inspection Cases in CFDI of NMPA. https://www.cfdi.org.cn/resource/news/14426.html; https://www.cfdi.org.cn/resource/news/14384.html; https://www.cfdi.org.cn/resource/news/13815.html.

9. WHO CPP Scheme in today’s Regulatory Environment – Is it Time for Change. WHO Drug Information Vol. 29, No.4. (2015).

10. Certification Scheme on the Quality of Pharmaceutical Products Moving in International commerce: Questions and Answers, WHO Drug Information Vol. 30, No. 3. (2016).

11. US FDA Center for Biologics Evaluation and. Emergency Use Authorization for Vaccines Explained FDA, (2020). https://www.fda.gov/vaccines-blood-biologics/vaccines/emergency-use-authorization-vaccines-explained.

12. IFPMA Serialization and Product Verification-Helping to Secure the Legal Supply Chain for Greater Patient Safety, 1–4 (2014). Joint-Industry-Position-Paper-on-Serialization-and-Product-Verification.pdf (ifpma.org).

13. ICH Q12 (2019). https://database.ich.org/sites/default/files/Q12_Guideline_Step4_2019_1119.pdf.

14. WHO General Guidance of Variations to Multisource Pharmaceutical Products Annex 10, WHO Technical Report Series 966 (2016). https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/regulatory-standards/trs966-annex10.pdf?sfvrsn=5d94f486_2.

15. HSA New Initiatives for Registration of Therapeutic Products (2020). https://www.hsa.gov.sg/docs/default-source/hsrpb-tpb/industry-comms/site-specific-stability-update.pdf.

16. ICMRA Report on the Review of Regulatory Flexibilities/Agilities as Implemented by National Regulatory Authorities during Covid-19 Pandemic – December 2020 (2021). https://www.icmra.info/drupal/sites/default/files/2021/12/Regulatory_Flexibilities_during_COVID-19_Report.pdf.

17. Philippines FDA Circular No.2021–020 Revised Post-marketing Surveillance Requirements for New Drugs under Monitored Release (2021). https://www.fda.gov.ph/fda-circular-no-2021-020-revised-post-marketing-surveillance-requirements-for-new-drugs-under-monitored-release/.

18. Philippines FDA Circular No. 2020–0030 Guideline for the Use of the FDA eServices Portal System for License to Operate (LTO) Application of Drug Distributors, Drug Traders, Drugstores, Retail Outlets for Non-Prescription Drugs (RONPD), Clinical Research Organizations CRO), and Sponsor (2020). https://www.fda.gov.ph/fda-circular-no-2020-0030-guideline-for-the-use-of-the-fda-eservices-portal-system-for-license-to-operate-lto-application-of-drug-distributorsdrug-traders-drugstores-retail-outlet-for-non/.

19. Philippines FDA Advisory No. 2021–0999 Implementation of the Food and Drug Administration (FDA) E-services Portal System for Automatic Renewal (AR) Applications for Drug Products (2021). https://www.fda.gov.ph/fda-advisory-no-2021-0999-implementation-of-the-food-and-drug-administration-fda-eservices-portal-system-for-automatic-renewal-ar-applications-for-drug-products/.

20. Philippines FDA Advisory No. 2021–1790 Pilot Implementation of the Food and Drug Administration (FDA) eServices Portal System for Principal Certificate of Product Registration (PCPR) Conversion Applications for Drug Products (2021). https://www.fda.gov.ph/fda-advisory-no-2021-1790-pilot-implementation-of-the-food-and-drug-administration-fda-eservices-portal-system-for-principal-certificate-of-product-registration-pcpr-conversion-applications-for/.

21. Philippines FDA Administrative Order No. 2020–0044 Adoption of the Collaborative Procedure for the Accelerated Registration of World of Health Organization (WHO) – Prequalified Pharmaceutical Products and Vaccines (2020). https://www.fda.gov.ph/administrative-order-no-2020-0044-adoption-of-the-collaborative-procedure-for-the-accelerated-registration-of-world-of-health-organization-who-prequalified-pharmaceutical-products-and-vaccine/.

22. Philippines FDA Administrative Order No. 2020–0045 Establishing Facilitated Registration Pathways for Drug Products, including Vaccines and Biologics (2020). https://www.fda.gov.ph/administrative-order-no-2020-0045-establishing-facilitated-registration-pathways-for-drug-products-including-vaccines-and-biologicals/.

23. Philippines FDA Circular No. 2020–036 Guidelines on the Issuance of Emergency Use Authorization for Drugs and Vaccines for Covid-19 (2020). https://www.fda.gov.ph/fda-circular-no-2020-036-guidelines-on-the-issuance-of-emergency-use-authorization-for-drugs-and-vaccines-for-covid-19/.

24. ASEAN Joint Assessment Procedure for Pharmaceutical Products Information for Applicants (2020). ASEAN Joint Assessment Procedure for Pharmaceutical Products Information for applicants (npra.gov.my).

25. PhAMA Position on Value Recommendations for ASEAN Joint Assessment Procedure (2021). https://www.phama.org.my/index.cfm?&menuid=88&parentid=117.
28. ACCESS Consortium; (2021). https://www.hsa.gov.sg/therapeutic-products/international-collaboration/access.

29. Project Orbis; A Framework for Concurrent Submission and Review of Oncology Products (2019). https://www.fda.gov/about-fda/ oncology-center-excellence/project-orbis.

30. NPRA Malaysia Variation Guideline for Pharmaceutical Products (2013). https://www.npra.gov.my/index.php/en/component/content/article/138-english/guidelines-general/1539-malaysia-variation-guideline-for-pharmaceutical-products-2013-first-edition.html?Itemid=1391.

31. Katkade VB, Sanders KN, Zou KH. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscip Healthc. 2018;2018(11):295–304. https://doi.org/10.2147/JMDH.S160029.

32. ASEAN Pharmaceutical Regulatory Policy Draft Version of August 31, 2021 (2021). https://www.fda.gov/wp-content/uploads/2021/09/ASEAN-PHARMACEUTICAL-REGULATORY-POLICY-1.pdf.

33. Discussion on the ASEAN Pharmaceutical Regulatory Policy (APRP) (2021). https://ariseplus.asean.org/discussion-on-aprp/#:~:text=The%20APRP%20is%20intended%20to,ASEAN%20Pharmaceutical%20Regulatory%20Framework%20Agreement.

34. Pan American Health Organization (PAHO) COVID-19 Information Systems and Digital Health (2020). https://iris.paho.org/handle/10665.2/52439.

35. Hong Kong Guidance Notes on Change of Registered Particulars of Registered Pharmaceutical Products/Substances version Nov 2021: 4 & 7 (2021). https://www.drugoffice.gov.hk/eps/do/en/doc/guidelines_forms/copGuide.pdf?v=lvxgyq.

36. Philippines FDA Circular No. 2022-004 Implementing Guidelines on the Abridged and Verification Pathways for New Drug Registration Applications in accordance with Administrative Order No. 2020-0045 “Establishing Facilitated Registration Pathways for Drug Products including Vaccines and Biologicals”. https://www.fda.gov.ph/fda-circular-no-2022-004-implementing-guidelines-on-the-bridged-and-verification-review-pathways-for-new-drug-registration-applications-in-accordance-with-administrative-order-no-2020-0045/

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.